SynthesisCancer medicine2026
RGS Family Remodeling in Breast Cancer: A Meta-Analysis and Multi-Omics Profiling of Prognostic Biomarkers.
Synthesis in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is a heterogeneous malignancy with diverse molecular subtypes and variable clinical outcomes. Despite diagnostic and therapeutic advances, recurrence and metastasis contribute to poor prognosis in subsets of patients. Regulators of G protein signaling (RGS) proteins, negative modulators of G protein-coupled receptor (GPCR) pathways, influence tumor progression, but their expression profiles, genomic alterations, immune associations, and prognostic roles in BC remain incompletely understood. This study systematically investigated the RGS family to identify potential biomarkers and therapeutic targets.
methodsTranscriptomic and clinical data from TCGA and seven independent GEO datasets were evaluated. A random-effects meta-analysis established cross-cohort expression consensus. Diagnostic value was assessed via ROC curve analysis. A prognostic signature was constructed using LASSO and multivariate Cox regression. Genomic alterations, DNA methylation, immune mapping, and pharmacogenomic profiling (DepMap/Broad Institute) were comprehensively analyzed.
resultsMeta-analysis identified eight robustly dysregulated RGS genes across BC cohorts. A combined 8-gene panel demonstrated diagnostic accuracy (AUC = 0.98). Furthermore, a LASSO-derived 6-gene signature successfully stratified patients into high- and low-risk prognostic groups (p < 0.0001). Immune infiltration profiling, validated by scRNA-seq, confirmed that RGS18 expression is robustly correlated with immune cells and originates predominantly from the tumor microenvironment rather than malignant cells.
conclusionsThis study identifies the RGS gene family as a multidimensional framework for BC stratification. Through meta-analysis, we confirmed that RGS3 and RGS4 act as independent oncogenic risk factors, while RGS1 and RGS18 serve as key immunoregulatory biomarkers. We established a high-accuracy 8-gene diagnostic panel (AUC = 0.98) and a 6-gene prognostic signature (RGS1, 2, 3, 10, 16, 19) that independently predicts patient survival. Our findings reveal that these dysregulations are driven by genomic amplifications and CpG methylation. These results position the RGS family as robust clinical biomarkers and actionable targets for precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.